IGF1 and neoplasm: These pathways are commonly deregulated in tumor cells, thus providing a mechanistic link between insulin/IGF1 and cancer initiation and progression via enhanced cancer cellular motility and invasion, anaerobic metabolism, dysregulation of epithelial to mesenchymal transition (EMT), tissue inflammation, reactive oxygen species (ROS) production, and angiogenesis, among others [21,23].